Lund-based biotech company Alligator Bioscience recently announced safety data from the phase II trial with lead candidate mitazalimab in pancreatic cancer in combination with chemotherapy mFOLFIRINOX. CEO Søren Bregenholt visited BioStock’s studio in Lund to comment on the data and to update on the ongoing activites in the company.
Watch the full interview with Alligator Bioscience‘s CEO Søren Bregenholt in the link below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.